$190.30
0.11% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US07725L1026
Symbol
BGNE
Sector
Industry

BeiGene Ltd. Sponsored ADR Stock price

$190.30
-22.51 10.58% 1M
+37.59 24.62% 6M
+9.94 5.51% YTD
+7.34 4.01% 1Y
-161.21 45.86% 3Y
-15.18 7.39% 5Y
+161.98 571.96% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.21 0.11%
ISIN
US07725L1026
Symbol
BGNE
Sector
Industry

Key metrics

Market capitalization $18.53b
Enterprise Value $16.92b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 5.10
P/S ratio (TTM) P/S ratio 5.59
P/B ratio (TTM) P/B ratio 5.90
Revenue growth (TTM) Revenue growth 50.46%
Revenue (TTM) Revenue $3.32b
EBIT (operating result TTM) EBIT $-872.57m
Free Cash Flow (TTM) Free Cash Flow $-994.57m
Cash position $2.71b
EPS (TTM) EPS $-8.24
P/E forward negative
P/S forward 5.03
EV/Sales forward 4.59
Short interest 2.10%
Show more

Is BeiGene Ltd. Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

BeiGene Ltd. Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

33 Analysts have issued a BeiGene Ltd. Sponsored ADR forecast:

30x Buy
91%
3x Hold
9%

Analyst Opinions

33 Analysts have issued a BeiGene Ltd. Sponsored ADR forecast:

Buy
91%
Hold
9%

Financial data from BeiGene Ltd. Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
3,317 3,317
50% 50%
100%
- Direct Costs 660 660
55% 55%
20%
2,656 2,656
49% 49%
80%
- Selling and Administrative Expenses 1,590 1,590
19% 19%
48%
- Research and Development Expense 1,794 1,794
8% 8%
54%
-727 -727
40% 40%
-22%
- Depreciation and Amortization 145 145
78% 78%
4%
EBIT (Operating Income) EBIT -873 -873
32% 32%
-26%
Net Profit -860 -860
10% 10%
-26%

In millions USD.

Don't miss a Thing! We will send you all news about BeiGene Ltd. Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BeiGene Ltd. Sponsored ADR Stock News

Neutral
Business Wire
about one hour ago
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it will participate in fireside chats at two upcoming investor conferences: Citizens JMP Hematology and Oncology Summit on Monday, December 2 at 1:00 p.m. ET; and Citi's Global Healthcare...
Neutral
PRNewsWire
7 days ago
Julia Wang Named Chief Financial Officer Beginning December 2, 2024 BURLINGTON, N.C. , Nov. 19, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that Executive Vice President and Chief Financial Officer (CFO) Glenn Eisenberg will retire from the company and Julia Wang will join on December 2, 2024, as Executive Vice Pr...
Neutral
Business Wire
7 days ago
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company which intends to change its name to BeOne Medicines Ltd., today announced it has entered into a settlement agreement with MSN Pharmaceuticals, Inc. and MSN Laboratories Private Ltd. resolving patent litigation related to MSN's Abbreviated New Drug Application ...
More BeiGene Ltd. Sponsored ADR News

Company Profile

BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.

Head office Cayman Islands
CEO John Oyler
Employees 10,000
Founded 2010
Website www.beigene.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today